Observation of nab-paclitaxel as first-line treatment in 40 elderly patients with ad-vanced lung squamous carcinoma
10.3969/j.issn.1000-8179.2018.08.934
- VernacularTitle:白蛋白结合型紫杉醇一线治疗40例晚期肺鳞癌的观察
- Author:
Jianguang LIN
1
;
Tianwen XU
;
Deqiang FU
;
Aiyue ZHAO
;
Yijun DAI
;
Jinzhi LAI
;
Yangbin DAI
Author Information
1. 福建医科大学附属第二医院肿瘤内科 福建省泉州市362000
- Keywords:
elderly;
advanced lung cancer;
squamous carcinoma;
nab-paclitaxel
- From:
Chinese Journal of Clinical Oncology
2018;45(8):394-397
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the clinical efficacy,toxicity,and prognostic factors of nab-paclitaxel as first-line treatment for elderly patients with advanced lung squamous carcinoma.Methods:This was a prospective study.Forty patients enrolled in the Second Affili-ated Hospital of Fujian Medical University were treated with nab-paclitaxel(260 mg/m2,ivggt d1),and a period of three weeks was considered as one session.The effects were evaluated after two cycles.Results:All 40 patients were followed up and appraised.Two patients achieved complete remission,13 achieved partial remission,13 achieved stable disease,and 12 achieved progressive disease. The objective response rate was 37.5% and the disease control rate was 70.0%.The progression-free survival(PFS),median overall sur-vival,and 1-year survival rate was 6.3 months,12.6 months,and 62.5%,respectively.The main hematologic toxicities were neutrope-nia and anemia,and the main non-hematologic adverse events were fatigue,constipation,nausea,vomiting,muscle aches,and hear-ing loss.Most patients could tolerate these toxic reactions.Moreover,Cox multivariate regression analysis showed that the neoplasm stage,Eastern Cooperative Oncology Group performance status,response rate,and PFS were independent factors for the survival rate (P<0.05),while age was not related to patient prognosis(P>0.05).Conclusions:Nab-paclitaxel as single drug and first-line therapy for elderly patients with advanced lung squamous carcinoma is effective and safe.
